Pacira BioSciences' Total Current Liabilities fell 65.05% to $107.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $107.1 million, marking a year-over-year decrease of 65.05%. This contributed to the annual value of $309.9 million for FY2024, which is 218.25% up from last year.
Pacira BioSciences' Total Current Liabilities amounted to $107.1 million in Q3 2025, which was down 65.81% from $313.2 million recorded in Q2 2025.
Pacira BioSciences' Total Current Liabilities' 5-year high stood at $521.1 million during Q4 2021, with a 5-year trough of $92.7 million in Q2 2024.
Its 3-year average for Total Current Liabilities is $176.0 million, with a median of $107.1 million in 2025.
In the last 5 years, Pacira BioSciences' Total Current Liabilities slumped by 71.64% in 2022 and then spiked by 237.86% in 2025.
Over the past 5 years, Pacira BioSciences' Total Current Liabilities (Quarterly) stood at $521.1 million in 2021, then crashed by 71.64% to $147.8 million in 2022, then crashed by 34.10% to $97.4 million in 2023, then spiked by 218.25% to $309.9 million in 2024, then tumbled by 65.05% to $107.1 million in 2025.
Its Total Current Liabilities was $107.1 million in Q3 2025, compared to $313.2 million in Q2 2025 and $314.7 million in Q1 2025.

Peer Comparison

Historic Data

Download Data 🔒

Date	Value